LYDERM 0.05 %
FLUOCINONIDE : 0.05 % · DIN 00716863 · TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC.
Health Canada status: MARKETED
What is LYDERM?
LYDERM 0.05 % contains FLUOCINONIDE : 0.05 %. It is listed in the Health Canada Drug Product Database under DIN 00716863, held by TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC., supplied as CREAM for TOPICAL administration. Health Canada currently lists it as marketed, status dated 06-Dec-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00716863 |
|---|---|
| Brand name | LYDERM |
| Generic / active ingredient | FLUOCINONIDE : 0.05 % |
| Manufacturer | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. |
| Strength | 0.05 % |
| Dosage form | CREAM |
| Route of administration | TOPICAL |
| Schedule | Prescription |
| ATC code | D07AC08 FLUOCINONIDE |
| AHFS class | 84:06.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 06-Dec-2023 |
| Original market date | 1988-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code D07AC08 FLUOCINONIDE. 4 of 18 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| LYDERM | 0.05 % | GEL | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. | MARKETED | DIN 02236997 |
| LYDERM | 0.05 % | OINTMENT | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. | MARKETED | DIN 02236996 |
| TIAMOL CREAM 0.05% | 0.05 % | CREAM | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. | MARKETED | DIN 00598933 |
| LIDEMOL | 0.05 % | CREAM | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 02163152 |
| LIDEMOL 0.05% | Strength | Cream , Emulsion | SYNTEX INC. 2455 Meadowpine Blvd. Mississauga Ontario Canada L5N 6L7 | CANCELLED POST MARKET | DIN 00424943 |
| LIDEX | 0.05 % | CREAM | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 02161923 |
| LIDEX | 0.05 % | OINTMENT | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 02161966 |
| LIDEX | 0.05 % | GEL | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 02161974 |
| LIDEX CREAM MILD 0.01% | 0.01 % | CREAM | MEDICIS CANADA LTD. | CANCELLED POST MARKET | DIN 00274453 |
| LIDEX OINTMENT MILD 0.01% | 0.01 % | OINTMENT | MEDICIS CANADA LTD. | CANCELLED POST MARKET | DIN 00274445 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.